Seattle Genetics Inc. (SGEN) and Takeda Pharmaceutical announced Monday morning that their Phase 3 study of ADCETRIS, in patients with Hodgkin lymphoma, met its primary endpoint of statistically significant improvement in modified progression-free survival.
from RTT - Before the Bell http://ift.tt/2thKzKH
via IFTTT
No comments:
Post a Comment